📰 Advicenne News
Page 2 - Advicenne News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Advicenne. Real-time updates on events, politics, business and more.
December 5, 2022
05.12.2022 - Regulatory News: Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, today announced the receipt ...
November 30, 2022
30.11.2022 - Regulatory News: Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, releases its financial ...
November 3, 2022
Regulatory News: Advicenne (Euronext Growth Paris ALDVI FR0013296746) (Paris:ALDVI), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those
October 5, 2022
Supplementary certificates extend Sibnayal protection to 2036 in several European countries Regulatory News: Advicenne (Euronext Growth Paris ALDVI FR0013296746) (Paris:ALDVI), a specialty pharmaceutical
September 14, 2022
Regulatory News: Advicenne (Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from
June 28, 2022
Advicenne signs its first Sibnayal distribution agreement outside Europe with Taïba Healthcare, one of the rare disease leading pharmaceutical company in Middle East - Advicenne will receive a transfer
June 10, 2022
Changes in governance with the appointment of a new Chairman of the Board of Directors and a new Director Regrouping of all French Advicenne's teams in the new Paris headquarters to optimize
June 9, 2022
Regulatory News: Advicenne (Euronext Growth Paris ALDVI FR0013296746) (Paris:ALDVI), announces that its Combined General Meeting held on June 9, 2022, authorized the Board of Directors for a period
April 21, 2022
Regulatory News: Advicenne (Euronext Growth Paris ALDVI -FR0013296746) (Paris:ALDVI), a pharmaceutical company specializing in the development and commercialization of innovative treatments for those
April 5, 2022
Regulatory News: Advicenne (Euronext: ALDVI) (Paris:ALDVI), a pharmaceutical company specializing in the development and commercialization of innovative treatments for those suffering from rare renal